Table 2. Percentage of patients entering into trial for TYA-specific tumours aged 0–24 years between 1 April 2005–31 March 2007.

Portfolio	1 April 2005–31 March 2006	1 April 2006–31 March 2007	% Change
Bone
0–4 years	0.0	66.6	+66.6
5–9 years	37.5	68.7	+31.2
10–14 years	56.3	100.0	+43.7
15–19 years	22.2	73.3	+51.1
20–24 years	28.6	42.8	+14.2
Children aged 5–14 years	46.9	100.0	+53.1
Older teenagers and young adults, 15–24 years	24.2	63.6	+39.4
Brain and central nervous system
0–4 years	28.4	29.7	+1.3
5–9 years	20.0	32.9	+12.9
10–14 years	18.3	20.7	+2.4
15–19 years	17.9	10.3	−7.6
20–24 years	0.0	0.0	0.0
Children aged 5–14 years	19.1	26.3	+7.2
Older teenagers and young adults, 15–24 years	8.6	4.9	−3.7
Germ cell
0–4 years	0.0	100.0	+100.0
5–9 years	0.0	0.0	0.0
10–14 years	0.0	0.0	0.0
15–19 years	5.2	3.4	−1.8
20–24 years	2.3	3.1	+0.8
Children aged 5–14 years	0.0	0.0	0.0
Older teenagers and young adults, 15–24 years	3.2	3.2	0.0
Leukaemia
0–4 years	84.1	77.7	−6.4
5–9 years	99.1	85.5	−13.6
10–14 years	100.0	100.0	+0.0
15–19 years	91.5	77.5	−14.0
20–24 years	92.9	48.2	−44.7
Children aged 5–14 years	100.0	91.3	−8.7
Older teenagers and young adults, 15–24 years	92.3	64.5	−27.8
Lymphoma
0–4 years	5.0	10.0	+5.0
5–9 years	0.0	3.2	+3.2
10–14 years	8.6	2.5	−6.1
15–19 years	4.5	4.5	0.0
20–24 years	8.3	7.8	−0.5
Children aged 5–14 years	6.3	2.6	+3.7
Older teenagers and young adults, 15–24 years	6.6	6.3	+0.3